An Insulin-Like Growth Factor-I Promoter Polymorphism Is Associated With Increased Mortality in Subjects With Myocardial Infarction in an Elderly Caucasian Population
We investigated whether an insulin-like growth factor I (IGF-I) promoter polymorphism is associated with excess mortality in elderly subjects with myocardial infarction (MI). This association was assessed in 7,983 subjects of the Rotterdam Study during 14 years of follow-up. Among 345 subjects who developed a MI, the risk of mortality was 1.49 times higher in the variant carriers of the IGF-I promoter polymorphism than in the nonvariant carriers (95% confidence interval 1.10 to 2.10, p = 0.02). The risk of death increased with the number of variant alleles. Our study suggests that genetically determined low IGF-I activity is an important determinant of mortality in subjects with MI.
To access this article, please choose from the options below
The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University, Rotterdam; Organization for Scientific Research, The Netherlands Organization for Health Research and Development, the Research Institute for Diseases in the Elderly, the Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sports, and the European Commission (DG XII), The Hague; the Municipality of Rotterdam, Rotterdam; and the Centre for Medical Systems Biology, Leiden, The Netherlands.
PII: S0002-9149(06)00175-5
doi:10.1016/j.amjcard.2005.11.069
© 2006 Elsevier Inc. All rights reserved.
